Vaxcyte, Inc. Common Stock

Vaxcyte trades at an $8.2B valuation despite posting no earnings, placing it squarely in the pre-revenue biotech zone where fundamentals feel almost irrelevant. The 10% short interest and RSI of 41 suggest moderate conviction on both sides, with the stock neither deeply oversold nor overbought—a rare equilibrium for an unprofitable company. Trading below its 52-week high is noteworthy given biotech's recent rally, implying either sector rotation or company-specific skepticism. Without P/E anchoring, valuation hinges entirely on pipeline hope and cash runway, making this a classic binary-outcome story where sentiment swings can be violent.